Phase II trial of daily S ‐1 combined with weekly irinotecan in previously treated patients with advanced or recurrent squamous cell lung cancer: North Japan lung cancer group 1101

ConclusionsAlthough the treatment-related adverse events were manageable, the combination of weekly irinotecan and S-1 did not have the expected effect.

Source: Thoracic Cancer - August 17, 2023 Category: Cancer & Oncology Authors: Yosuke Kawashima, Osamu Ishimoto, Eisaku Miyauchi, Tomohiro Sakakibara, Toshiyuki Harada, Kazuhiro Usui, Akira Inoue, Shunichi Sugawara Tags: ORIGINAL ARTICLE Source Type: research